Skip to content

Clinical trials

Observational Myocardial Infarction trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myocardial Infarction Phase: Observational Country / region: China Clear all

50 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20071
20091
20101
20111
20121
20132
20142
20152
20162
20173
20185
20193
20203
20213
20224
20233
20242
20253
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Unknown status14
Recruiting10
Not yet recruiting7
Enrolling by invitation2
Active, not recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shanghai 10th People's Hospital5
Qilu Hospital of Shandong University4
Beijing Anzhen Hospital3
Chinese PLA General Hospital3
Chinese Academy of Medical Sciences, Fuwai Hospital2
Second Affiliated Hospital, Zhejiang University, School of Medicine2
The Affiliated Hospital of Xuzhou Medical University2
Xijing Hospital2
Amgen1
AstraZeneca1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myocardial Infarction50
Coronary Artery Disease6
ST Elevation Myocardial Infarction6
Atrial Fibrillation4
Cardiovascular Diseases4
Myocardial Ischemia4
Acute Coronary Syndrome3
Angina Pectoris3
Coronary Disease3
Diabetes Mellitus3

Trials

Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.